Early Switch to Atezolizumab After Vemurafenib/Cobimetinib Run-in Shows Improved Survival Trend in Melanoma
Patients with BRAF V600–positive melanoma demonstrated a trend toward improved survival at 4 and 5 months with an earlier switch to atezolizumab (Tecentriq) after run-in with vemurafenib (Zelboraf) plus cobimetinib (Cotellic). However, the improvement was …